[A recombinant human nonglycosylated interleukin-1 (IL-1) receptor antagonist with potential antineoplastic activity. Anakinra binds to the IL-1 receptor, thereby blocking the binding of the IL-1 to and activation of its receptor. Blockade of IL-1 activity may inhibit the cascade of downstream pro-angiogenic factors such as vascular endothelial cell growth factor, tumor necrosis factor-alpha, and IL-6, resulting in inhibition of tumor angiogenesis. (NCI04) ( NCI )]
UMLS (NCI) C0245109 - Amino Acid, Peptide, or Protein
- Pharmacologic Substance
Relation/PAR: [MS109] ANTIRHEUMATICS, OTHER
Unclassified Ingredients
Relation/CHD: ANAKINRA 100 MG